GTSF1 Activators
GTSF1 Activators are a unique class of compounds that function primarily by influencing the PI3K/AKT/mTOR pathway and the MAPK pathway, both of which GTSF1 is directly involved in. The compounds Akti-1/2, Wortmannin, Perifosine, and ZSTK474 operate within the PI3K/AKT/mTOR pathway. Their primary mechanism of action involves inhibiting key components like mTOR, PI3K, and AKT. The inhibition of these components results in the activation of GTSF1, thereby enhancing its role in this pathway. This activation is a crucial aspect of cellular signaling and the regulation of vital processes within the cell.
The other subset of GTSF1 Activators, namely PD98059, SP600125, SB203580, FR180204, and PD0325901, act within the MAPK pathway. They work by inhibiting key components like MEK1/2, JNK, p38 MAPK, and ERK. This inhibition activates GTSF1, thereby enhancing its role within the MAPK pathway. This specific activation of GTSF1 via the MAPK pathway provides an additional layer of control within cellular signaling, offering a detailed insight into the complex network of interactions that govern cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 is an AKT inhibitor. GTSF1 is involved in the PI3K/AKT/mTOR pathway. By inhibiting AKT, Akti-1/2 can lead to the activation of GTSF1, which can further participate in the regulation of the PI3K/AKT/mTOR pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor. GTSF1 is involved in the MAPK pathway. By inhibiting MEK, PD98059 can lead to the activation of GTSF1, which can further participate in the regulation of the MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. JNK is part of the MAPK pathway, in which GTSF1 is involved. By inhibiting JNK, SP600125 can lead to the activation of GTSF1, which can further participate in the regulation of the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. p38 MAPK is part of the MAPK pathway, in which GTSF1 is involved. By inhibiting p38 MAPK, SB203580 can lead to the activation of GTSF1, which can further participate in the regulation of the MAPK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. GTSF1 is involved in the PI3K/AKT/mTOR pathway. By inhibiting PI3K, Wortmannin can lead to the activation of GTSF1, which can further participate in the regulation of the PI3K/AKT/mTOR pathway. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an AKT inhibitor. GTSF1 is involved in the PI3K/AKT/mTOR pathway. By inhibiting AKT, Perifosine can lead to the activation of GTSF1, which can further participate in the regulation of the PI3K/AKT/mTOR pathway. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a PI3K inhibitor. GTSF1 is involved in the PI3K/AKT/mTOR pathway. By inhibiting PI3K, ZSTK474 can lead to the activation of GTSF1, which can further participate in the regulation of the PI3K/AKT/mTOR pathway. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204 is an ERK inhibitor. ERK is part of the MAPK pathway, in which GTSF1 is involved. By inhibiting ERK, FR180204 can lead to the activation of GTSF1, which can further participate in the regulation of the MAPK pathway. | ||||||